@article{SchulteBlum2022,
  author    = {Schulte, Annemarie and Blum, Robert},
  title     = {Shaped by leaky ER: Homeostatic Ca\(^{2+}\) fluxes},
  series = {Frontiers in Physiology},
  volume    = {13},
  journal   = {Frontiers in Physiology},
  issn      = {1664-042X},
  doi       = {10.3389/fphys.2022.972104},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-287102},
  year      = {2022},
  abstract  = {At any moment in time, cells coordinate and balance their calcium ion (Ca\(^{2+}\)) fluxes. The term 'Ca\(^{2+}\) homeostasis' suggests that balancing resting Ca2+ levels is a rather static process. However, direct ER Ca\(^{2+}\) imaging shows that resting Ca\(^{2+}\) levels are maintained by surprisingly dynamic Ca\(^{2+}\) fluxes between the ER Ca\(^{2+}\) store, the cytosol, and the extracellular space. The data show that the ER Ca\(^{2+}\) leak, continuously fed by the high-energy consuming SERCA, is a fundamental driver of resting Ca\(^{2+}\) dynamics. Based on simplistic Ca\(^{2+}\) toolkit models, we discuss how the ER Ca\(^{2+}\) leak could contribute to evolutionarily conserved Ca\(^{2+}\) phenomena such as Ca\(^{2+}\) entry, ER Ca\(^{2+}\) release, and Ca\(^{2+}\) oscillations.},
  language  = {en}
}
@article{BerveWestMartinietal.2020,
  author    = {Berve, Kristina and West, Brian L. and Martini, Rudolf and Groh, Janos},
  title     = {Sex- and region-biased depletion of microglia/macrophages attenuates CLN1 disease in mice},
  series = {Journal of Neuroinflammation},
  volume    = {17},
  journal   = {Journal of Neuroinflammation},
  doi       = {10.1186/s12974-020-01996-x},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-230234},
  year      = {2020},
  abstract  = {Background The neuronal ceroid lipofuscinoses (CLN diseases) are fatal lysosomal storage diseases causing neurodegeneration in the CNS. We have previously shown that neuroinflammation comprising innate and adaptive immune reactions drives axonal damage and neuron loss in the CNS of palmitoyl protein thioesterase 1-deficient (Ppt1\(^{-/-}\)) mice, a model of the infantile form of the diseases (CLN1). Therefore, we here explore whether pharmacological targeting of innate immune cells modifies disease outcome in CLN1 mice. Methods We applied treatment with PLX3397 (150 ppm in the chow), a potent inhibitor of the colony stimulating factor-1 receptor (CSF-1R) to target innate immune cells in CLN1 mice. Experimental long-term treatment was non-invasively monitored by longitudinal optical coherence tomography and rotarod analysis, as well as analysis of visual acuity, myoclonic jerks, and survival. Treatment effects regarding neuroinflammation, neural damage, and neurodegeneration were subsequently analyzed by histology and immunohistochemistry. Results We show that PLX3397 treatment attenuates neuroinflammation in CLN1 mice by depleting pro-inflammatory microglia/macrophages. This leads to a reduction of T lymphocyte recruitment, an amelioration of axon damage and neuron loss in the retinotectal system, as well as reduced thinning of the inner retina and total brain atrophy. Accordingly, long-term treatment with the inhibitor also ameliorates clinical outcomes in CLN1 mice, such as impaired motor coordination, visual acuity, and myoclonic jerks. However, we detected a sex- and region-biased efficacy of CSF-1R inhibition, with male microglia/macrophages showing higher responsiveness toward depletion, especially in the gray matter of the CNS. This results in a better treatment outcome in male Ppt1\(^{-/-}\) mice regarding some histopathological and clinical readouts and reflects heterogeneity of innate immune reactions in the diseased CNS. Conclusions Our results demonstrate a detrimental impact of innate immune reactions in the CNS of CLN1 mice. These findings provide insights into CLN pathogenesis and may guide in the design of immunomodulatory treatment strategies.},
  language  = {en}
}
@article{NotzLotzHerrmannetal.2021,
  author    = {Notz, Quirin and Lotz, Christopher and Herrmann, Johannes and Vogt, Marius and Schlesinger, Tobias and Kredel, Markus and Muellges, Wolfgang and Weismann, Dirk and Westermaier, Thomas and Meybohm, Patrick and Kranke, Peter},
  title     = {Severe neurological complications in critically ill COVID‑19 patients},
  series = {Journal of Neurology},
  journal   = {Journal of Neurology},
  issn      = {0340-5354},
  doi       = {10.1007/s00415-020-10152-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-232429},
  pages     = {1576-1579},
  year      = {2021},
  abstract  = {No abstract available.},
  language  = {en}
}
@article{TraubOttoSelletal.2022,
  author    = {Traub, Jan and Otto, Markus and Sell, Roxane and G{\"o}pfert, Dennis and Homola, Gy{\"o}rgy and Steinacker, Petra and Oeckl, Patrick and Morbach, Caroline and Frantz, Stefan and Pham, Mirko and St{\"o}rk, Stefan and Stoll, Guido and Frey, Anna},
  title     = {Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients},
  series = {Alzheimer's Research \& Therapy},
  volume    = {14},
  journal   = {Alzheimer's Research \& Therapy},
  doi       = {10.1186/s13195-022-01087-4},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-300515},
  year      = {2022},
  abstract  = {Background Chronic heart failure (HF) is known to increase the risk of developing Alzheimer's dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Serum biomarkers are increasingly used in neurological disorders for diagnostics, monitoring, and prognostication of disease course. It remains unclear if neuronal biomarkers may help detect cognitive impairment in this high-risk population. Also, the influence of chronic HF and concomitant renal dysfunction on these biomarkers is not well understood. Methods Within the monocentric Cognition.Matters-HF study, we quantified the serum levels of phosphorylated tau protein 181 (pTau) and neurofilament light chain (NfL) of 146 extensively phenotyped chronic heart failure patients (aged 32 to 85 years; 15.1\% women) using ultrasensitive bead-based single-molecule immunoassays. The clinical work-up included advanced cognitive testing and cerebral magnetic resonance imaging (MRI). Results Serum concentrations of NfL ranged from 5.4 to 215.0 pg/ml (median 26.4 pg/ml) and of pTau from 0.51 to 9.22 pg/ml (median 1.57 pg/ml). We detected mild cognitive impairment (i.e., T-score < 40 in at least one cognitive domain) in 60\% of heart failure patients. pTau (p = 0.014), but not NfL, was elevated in this group. Both NfL (ρ = - 0.21; p = 0.013) and pTau (ρ = - 0.25; p = 0.002) related to the cognitive domain visual/verbal memory, as well as white matter hyperintensity volume and cerebral and hippocampal atrophy. In multivariable analysis, both biomarkers were independently influenced by age (T = 4.6 for pTau; T = 5.9 for NfL) and glomerular filtration rate (T = - 2.4 for pTau; T = - 3.4 for NfL). Markers of chronic heart failure, left atrial volume index (T = 4.6) and NT-proBNP (T = 2.8), were further cardiological determinants of pTau and NfL, respectively. In addition, pTau was also strongly affected by serum creatine kinase levels (T = 6.5) and ferritin (T = - 3.1). Conclusions pTau and NfL serum levels are strongly influenced by age-dependent renal and cardiac dysfunction. These findings point towards the need for longitudinal examinations and consideration of frequent comorbidities when using neuronal serum biomarkers.},
  language  = {en}
}
@article{TraubOttoSelletal.2022,
  author    = {Traub, Jan and Otto, Markus and Sell, Roxane and Homola, Gy{\"o}rgy A. and Steinacker, Petra and Oeckl, Patrick and Morbach, Caroline and Frantz, Stefan and Pham, Mirko and St{\"o}rk, Stefan and Stoll, Guido and Frey, Anna},
  title     = {Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure},
  series = {ESC Heart Failure},
  volume    = {9},
  journal   = {ESC Heart Failure},
  number    = {4},
  doi       = {10.1002/ehf2.13986},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-312736},
  pages     = {2626-2634},
  year      = {2022},
  abstract  = {Aims Cognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary neurodegeneration such as Alzheimer's disease. We evaluated the utility of serum GFAP as a biomarker for cognitive dysfunction and structural brain damage in patients with stable chronic HF. Methods and results Using bead-based single molecule immunoassays, we quantified serum levels of GFAP in patients with HF participating in the prospective Cognition.Matters-HF study. Participants were extensively phenotyped, including cognitive testing of five separate domains and magnetic resonance imaging (MRI) of the brain. Univariable and multivariable models, also accounting for multiple testing, were run. One hundred and forty-six chronic HF patients with a mean age of 63.8 ± 10.8 years were included (15.1\% women). Serum GFAP levels (median 246 pg/mL, quartiles 165, 384 pg/mL; range 66 to 1512 pg/mL) did not differ between sexes. In the multivariable adjusted model, independent predictors of GFAP levels were age (T = 5.5; P < 0.001), smoking (T = 3.2; P = 0.002), estimated glomerular filtration rate (T = -4.7; P < 0.001), alanine aminotransferase (T = -2.1; P = 0.036), and the left atrial end-systolic volume index (T = 3.4; P = 0.004). NT-proBNP but not serum GFAP explained global cerebral atrophy beyond ageing. However, serum GFAP levels were associated with the cognitive domain visual/verbal memory (T = -3.0; P = 0.003) along with focal hippocampal atrophy (T = 2.3; P = 0.025). Conclusions Serum GFAP levels are affected by age, smoking, and surrogates of the severity of HF. The association of GFAP with memory dysfunction suggests that astroglial pathologies, which evade detection by conventional MRI, may contribute to memory loss beyond ageing in patients with chronic HF.},
  language  = {en}
}
@phdthesis{Schramm2002,
  author    = {Schramm, Axel},
  title     = {Sensomotorische Integration bei zervikalen Dystonien},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-4722},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2002},
  abstract  = {Zervikale Dystonien geh{\"o}ren zu den h{\"a}ufigsten Formen fokaler Dystonien. Diese sind durch anhaltende, unwillk{\"u}rliche Muskelkontraktionen gekennzeichnet, welche zu verdrehenden oder repetitiven Bewegungen oder abnormalen Haltungen des Kopfes f{\"u}hren. Ein seit {\"u}ber 100 Jahren beobachtetes Ph{\"a}nomen stellt hierbei die M{\"o}glichkeit dar, mittels sogenannter "sensibler Trickman{\"o}ver", welche meistens in einer leichten Ber{\"u}hrung von Arealen im Kopfbereich bestehen, die pathologische Muskelaktivit{\"a}t zu reduzieren und damit die Kopfposition zu normalisieren. Ziel der vorliegenden Arbeit war es, eine breite und vor allem erstmalig quantitative Charakterisierung von wirksamen Trickman{\"o}vern vorzunehmen und so verschiedene Einflußgr{\"o}ßen auf die Wirksamkeit solcher Tricks zu untersuchen. Hierzu wurden die Muskelaktivit{\"a}ten der vier wichtigsten den Kopf drehenden Muskeln mittels Oberfl{\"a}chen-EMG abgeleitet und die Ver{\"a}nderungen bei Trickapplikation unterschiedlicher Lokalisation, Modalit{\"a}t und bei verschiedenen Ausgangspositionen ermittelt. 1) Hinsichtlich der Lokalisation ergaben sich {\"u}ber alle Patienten gemittelt keine signifikante Seitendifferenz, und auch bei individuellem Vergleich zeigten sich bei rund 50\% der Patienten keine signifikanten Unterschiede zwischen kontralateraler und ipsilateraler Trickapplikation. Unter den getesteten Applikationsorten grenzte sich das Areal "Wange" mit durchschnittlich 33\%iger Reduktion der gesamten EMG-Aktivit{\"a}t signifikant gegen die Areale "Kinn" (-23\%) und "Hals" (-23\%) ab und war bei 79\% der Patienten am besten wirksam. 2) Bei weiterer Untersuchung verschiedener Trickmodalit{\"a}ten auf dem f{\"u}r jeden Patienten individuell wirksamsten Areal waren neben dem klassischen Trickman{\"o}ver (-42\%) auch die Verwendung eines Plastikstabes durch den Patienten (-43\%) oder Untersucher (-32\%), sowie nicht-sensible Man{\"o}ver wie das Heben des Armes ohne eigentliche Ber{\"u}hrung (-18\%) und die bloße Vorstellung einer Trickapplikation (-20\%) hochsignifikant wirksam. Allerdings korrelierten sensible und (wie die beiden letztgenannten) nicht-sensible Tricks nicht miteinander, was auf einen prinzipiell unterschiedlichen Wirkmechanismus hinweisen k{\"o}nnte. Visuelle R{\"u}ckkopplung {\"u}ber einen Spiegel hatte im Gegensatz dazu keine Wirkung. 3) Bez{\"u}glich der Bedeutung der Kopfposition f{\"u}r Muskelaktivit{\"a}t und Trickwirksamkeit zeigte sich bereits bei willk{\"u}rlicher Einnahme einer Neutralposition ohne Trickanwendung eine signifikante Reduktion agonistischer Muskelaktivit{\"a}t (-30\%), die allerdings von einer leichten antagonistischen Aktivierung begleitet war (+2,4\%). {\"U}berraschenderweise war die Applikation eines Tricks um so wirksamer, je weiter der Kopf zu Beginn auf die zur dystonen Drehrichtung kontralateralen Seite gedreht war. Demgegen{\"u}ber ließ sich bei Trickapplikation in dystoner Maximalposition kaum mehr eine Wirkung nachweisen (-12\%). Die vorliegenden Ergebnisse sprechen aufgrund der unspezifischen Wirkung verschiedenster Trickman{\"o}ver (2) und Lokalisationen (1) f{\"u}r die Einbeziehung h{\"o}herer sensomotorischer Integrationszentren wie z. B. des Parietalcortex in den Wirkmechanismus. Sensible Trickman{\"o}ver k{\"o}nnten bei auf die pathologische Kopfposition adaptierten sensiblen Afferenzen Zusatzinformationen {\"u}ber die Kopfposition im Vergleich zum Rumpf liefern. M{\"o}glicherweise sind diese umso wirksamer, je weiter sich der Kopf noch auf der kontralateralen Seite befindet (3), da in dieser Situation die dystone Muskelaktivit{\"a}t noch gering und das sensible Mismatch, {\"u}ber welches sensible Stimuli modulierend einwirken k{\"o}nnten, maximal ist. Nach den vorgelegten Ergebnissen l{\"a}ßt sich erstmals ein zweiphasiger Ablauf der Trickwirkung postulieren: Der in einer ersten Phase teils willk{\"u}rlich in eine g{\"u}nstige Ausgangsposition gebrachte Kopf kann durch die Anwendung sensibler Stimuli oder Imagination in einer zweiten Phase mit geringerer Anstrengung und unter Ausnutzung kortikaler sensomotorischer Servomechanismen stabilisiert werden. Im Rahmen der vorgelegten Studie konnte das Verst{\"a}ndnis f{\"u}r therapeutisch nutzbare sensible Trickman{\"o}ver verbessert und somit Patienten unterschiedliche Trickstrategien an die Hand gegeben werden. Die Identifikation der zentralen Rolle h{\"o}herer integrativer Zentren wie dem Parietalcortex im Rahmen des Wirkmechanismus, k{\"o}nnte dabei Ausgangspunkt f{\"u}r neue Therapieans{\"a}tze in Form einer gezielten Beeinflussung solcher Areale sein.},
  language  = {de}
}
@phdthesis{Nehring2003,
  author    = {Nehring, Claudia},
  title     = {Sensitivit{\"a}t elektrophysiologischer Parameter bei der chronischen inflammatorischen demyelinisierenden Polyneuropathie (CIDP) in der Beurteilung des Langzeitverlaufes},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-7659},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {Die Chronische Inflammatorische Demyelinisierende Polyneuropathie (CIDP) ist eine seltene autoimmune Erkrankung des peripheren Nervensystems. In der vorliegenden Dissertation wurden die Akten von 23 CIDP - Patienten der Neurologischen Klinik der Universit{\"a}t W{\"u}rzburg aus dem Zeitraum von 1990 bis 1999 ausgewertet und die elektrophysiologischen Parameter sowohl mit den klinischen Befunden als auch mit den Biopsiebefunden in Beziehung gestellt. Folgende Schlussfolgerungen konnten gezogen werden : - In dem untersuchten Patientenkollektiv war die sensomotorische Form der CIDP mit {\"u}berwiegend motorischen Symptomen die h{\"a}ufigste Auspr{\"a}gungsform. Hingegen treten rein motorische und rein sensible Formen sehr selten auf. - Die Krankheit manifestierte sich {\"u}berwiegend an den distalen Extremit{\"a}ten. - Die oberen Extremit{\"a}ten waren selten und in keinem Fall isoliert betroffen. - Die systematische Auswertung des klinischen Schwergrades erfolgte anhand des Modifizierten Rankin Scores, der sowohl motorische als auch sensible Symptome ber{\"u}cksichtigt. Zus{\"a}tzlich erfolgte der Entwurf eines sensiblen Scores, bei dem die sensiblen Symptome der Patienten in Zahlenwerten ausgedr{\"u}ckt sind. - Der Vergleich des klinischen Schweregrades mit den neurophysiologischen Befunden ergab vier unterschiedliche Korrelationstypen, die von sehr enger Korrelation bis hin zu nur geringen {\"U}bereinstimmungen reichten. - Der Schwergrad der Beeintr{\"a}chtigung der Patienten war im Langzeitverlauf mit dem axonalen Verlust korreliert. Es fand sich eine gute Korrelation der Muskelsummenaktionspotentiale (CMAP) des Nervus medianus und des Nervus tibialis sowie der sensiblen Nervenaktionspotentiale (SNAP) des Nervus suralis mit dem Score. - Es ergab sich ein signifikanter Zusammenhang zwischen der Amplitude des Nervus suralis NAP`s und dem Ausmaß des Axonverlustes, wohingegen zwischen der Nervenleitungsgeschwindigkeit des Nervus suralis und dem Axonverlust nur eine geringe Abh{\"a}ngigkeit besteht. - Der Grad der Demyelinisierung korrelierte mit der Anzahl der endoneuralen Makrophagen. - Zwischen der Nervenleitgeschwindigkeit des Nervus suralis und dem Grad der Demyelinisierung im Biopsat konnte keine eindeutige Abh{\"a}ngigkeit nachgewiesen werden. - Es besteht ein Zusammenhang zwischen der Spontanaktivit{\"a}t im EMG und im Verlauf abnehmenden Nervenleitgeschwindigkeiten des Nervus medianus, der aber statistisch nicht signifikant ist. - Insbesondere ist die NLG- Abnahme in den ersten Wochen ein prognostisch ung{\"u}nstiges Zeichen. - Eine Analogie zwischen einer durch das EMG nachgewiesenen Spontanaktivit{\"a}t und der Amplitude des Nervus suralis besteht. - Zwischen den Amplituden der motorischen Summenaktionspotentiale des Nervus tibialis oder den Amplituden der sensiblen Nervenaktionspotentiale des Nervus suralis auf der einen Seite und dem Ausmaß der Spontanaktivit{\"a}t im EMG auf der anderen Seite bestehen erkennbare Korrelationen.},
  language  = {de}
}
@article{MaggRieglerWiedmannetal.2015,
  author    = {Magg, Barbara and Riegler, Christoph and Wiedmann, Silke and Heuschmann, Peter and Sommer, Claudia and {\"U}{\c{c}}eyler, Nurcan},
  title     = {Self-administered version of the Fabry-associated pain questionnaire for adult patients},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {10},
  journal   = {Orphanet Journal of Rare Diseases},
  number    = {113},
  doi       = {10.1186/s13023-015-0325-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-145294},
  year      = {2015},
  abstract  = {Background Fabry-associated pain may be the first symptom of Fabry disease (FD) and presents with a unique phenotype including mostly acral burning triggerable pain attacks, evoked pain, pain crises, and permanent pain. We recently developed and validated the first Fabry Pain Questionnaire (FPQ) for adult patients. Here we report on the validation of the self-administered version of the FPQ that no longer requires a face-to-face interview but can be filled in by the patients themselves allowing more flexible data collection. Methods At our W{\"u}rzburg Fabry Center for Interdisciplinary Treatment, Germany, we have developed the self-administered version of the FPQ by adapting the questionnaire to a self-report version. To do this, consecutive Fabry patients with current or past pain history (n = 56) were first interviewed face-to-face. Two weeks later patients' self-reported questionnaire results were collected by mail (n = 55). We validated the self-administered version of the FPQ by assessing the inter-rater reliability agreement of scores obtained by supervised administration and self-administration of the FPQ. Results The FPQ contains 15 questions on the different pain phenotypes, on pain development during life with and without therapy, and on impairment due to pain. Statistical analysis showed that the majority of questions were answered in high agreement in both sessions with a mean AC1-statistic of 0.857 for 55 nominal-scaled items and a mean ICC of 0.587 for 9 scores. Conclusions This self-administered version of the first pain questionnaire for adult Fabry patients is a useful tool to assess Fabry-associated pain without a time-consuming face-to-face interview but via a self-reporting survey allowing more flexible usage.},
  language  = {en}
}
@article{BenKraiemSauerNorwigetal.2021,
  author    = {Ben-Kraiem, Adel and Sauer, Reine-Solange and Norwig, Carla and Popp, Maria and Bettenhausen, Anna-Lena and Atalla, Mariam Sobhy and Brack, Alexander and Blum, Robert and Doppler, Kathrin and Rittner, Heike Lydia},
  title     = {Selective blood-nerve barrier leakiness with claudin-1 and vessel-associated macrophage loss in diabetic polyneuropathy},
  series = {Journal of Molecular Medicine},
  volume    = {99},
  journal   = {Journal of Molecular Medicine},
  number    = {9},
  doi       = {10.1007/s00109-021-02091-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265237},
  pages     = {1237-1250},
  year      = {2021},
  abstract  = {Diabetic polyneuropathy (DPN) is the most common complication in diabetes and can be painful in up to 26\% of all diabetic patients. Peripheral nerves are shielded by the blood-nerve barrier (BNB) consisting of the perineurium and endoneurial vessels. So far, there are conflicting results regarding the role and function of the BNB in the pathophysiology of DPN. In this study, we analyzed the spatiotemporal tight junction protein profile, barrier permeability, and vessel-associated macrophages in Wistar rats with streptozotocin-induced DPN. In these rats, mechanical hypersensitivity developed after 2 weeks and loss of motor function after 8 weeks, while the BNB and the blood-DRG barrier were leakier for small, but not for large molecules after 8 weeks only. The blood-spinal cord barrier remained sealed throughout the observation period. No gross changes in tight junction protein or cytokine expression were observed in all barriers to blood. However, expression of Cldn1 mRNA in perineurium was specifically downregulated in conjunction with weaker vessel-associated macrophage shielding of the BNB. Our results underline the role of specific tight junction proteins and BNB breakdown in DPN maintenance and differentiate DPN from traumatic nerve injury. Targeting claudins and sealing the BNB could stabilize pain and prevent further nerve damage.},
  language  = {en}
}
@article{VolkmannAlbaneseAntoninietal.2013,
  author    = {Volkmann, Jens and Albanese, Alberto and Antonini, Angelo and Chaudhuri, K. Ray and Clarke, Karl E. and de Bie, Rob M. A. and Deuschl, G{\"u}nther and Eggert, Karla and Houeto, Jean-Luc and Kulisevsky, Jaime and Nyholm, Dag and Odin, Per and Ostergaard, Karen and Poewe, Werner and Pollak, Pierre and Rabey, Jose Martin and Rascol, Olivier and Ruzicka, Evzen and Samuel, Michael and Speelman, Hans and Sydow, Olof and Valldeoriola, Francesc and van der Linden, Chris and Oertel, Wolfgang},
  title     = {Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review},
  series = {Journal of Neurology},
  volume    = {260},
  journal   = {Journal of Neurology},
  doi       = {10.1007/s00415-012-6798-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-132373},
  pages     = {2701-2714},
  year      = {2013},
  abstract  = {Motor complications in Parkinson's disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine.},
  language  = {en}
}